166 related articles for article (PubMed ID: 15872136)
1. Candida albicans lung abscess sensitive to fluconazole and responding only to amphotericin B in a non-immunocompromised critically ill patient.
Liolios A; Gressens B; Leonard I; Coche E; Hantson P
Can J Anaesth; 2005 May; 52(5):544-5. PubMed ID: 15872136
[No Abstract] [Full Text] [Related]
2. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
3. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
4. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y
Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847
[No Abstract] [Full Text] [Related]
6. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
7. [Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Tapia C; González P; Pereira A; Pérez J; Noriega LM; Palavecino E
Rev Med Chil; 2003 May; 131(5):515-9. PubMed ID: 12879812
[TBL] [Abstract][Full Text] [Related]
8. Candida albicans-infected pancreatic pseudocyst: report of a case.
Zulfikaroglu B; Koc M; Ozalp N
Surg Today; 2004; 34(5):466-9. PubMed ID: 15108092
[TBL] [Abstract][Full Text] [Related]
9. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
10. Candida endophthalmitis: focus on current and future antifungal treatment options.
Khan FA; Slain D; Khakoo RA
Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
[TBL] [Abstract][Full Text] [Related]
11. Potential of plant oils as inhibitors of Candida albicans growth.
Devkatte AN; Zore GB; Karuppayil SM
FEMS Yeast Res; 2005 Jun; 5(9):867-73. PubMed ID: 15925315
[TBL] [Abstract][Full Text] [Related]
12. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
13. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
14. [Candida albicans spondylitis: successful treatment with fluconazole. 2 case reports].
Rösler-Meier D; Brunner-La Rocca HP; Senn P; Schlumpf U
Praxis (Bern 1994); 1996 Apr; 85(16):520-5. PubMed ID: 8657996
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
[TBL] [Abstract][Full Text] [Related]
16. Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis.
Le TP; Tuazon CU; Levine M; Borum M; Rollhauser C
Clin Infect Dis; 1996 Sep; 23(3):649-50. PubMed ID: 8879803
[No Abstract] [Full Text] [Related]
17. Resistance to antifungal agents in the critical care setting: problems and perspectives.
Martins MD; Rex JH
New Horiz; 1996 Aug; 4(3):338-44. PubMed ID: 8856751
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole therapy in Candida albicans spondylodiscitis.
Rössel P; Schønheyder HC; Nielsen H
Scand J Infect Dis; 1998; 30(5):527-30. PubMed ID: 10066061
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B.
Turner DL; Johnson SA; Rule SA
J Infect; 1999 Jan; 38(1):51-3. PubMed ID: 10090510
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of fluconazole in critically ill patients.
Sinnollareddy M; Peake SL; Roberts MS; Playford EG; Lipman J; Roberts JA
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1431-40. PubMed ID: 21883033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
